Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Merck $8 billion notes offering, including its debut sustainability debt
The offering includes five tranches of notes
CANbridge Pharmaceuticals HK$685 million IPO
We advised CANbridge Pharmaceuticals on its IPO and HKEX listing
Olympus $500 million senior notes offering
The debut offering consisted of 2.143% senior notes due 2026
Ingenovis Health acquisition of HealthCare Support Staffing
We are advising Cornell Capital, Trilantic Partners and Ingenovis Health on the transaction
Privia Health $174 million secondary offering
We advised Privia on its SEC-registered offering of stock
Alignment Healthcare $193 million SEC-registered secondary offering
The shares are listed on the Nasdaq Global Select Market
Novo Nordisk $3.3 billion acquisition of Dicerna Pharmaceuticals
We are advising Novo Nordisk on the transaction
BDT Capital Partners acquires a majority interest in MJH Life Sciences
We are advising BDT Capital Partners on the transaction
Apria $141.7 million secondary offering
The shares are listed on the Nasdaq Global Select Market
Revolution Medicines $250 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market